

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. Claims 7-10 have been amended. Claim 6 has been cancelled without prejudice for resubmission. New claims 14-20 have been added. Claims 1-5 and 7-20 are pending after entry of this amendment. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Newly added claims are supported by the original claims. No new matter has been added by these amendments.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100952-1P US.

Respectfully submitted,

July 7, 2005



Kenneth F. Mitchell for Jianzhong Shen
Name: Kenneth F. Mitchell
Dated: July 7, 2005
Reg. No. 42,007
Phone No. 302-886-7466
Name: Jianzhong Shen
Reg. No. 48,076
Phone No. 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437